Patents Assigned to RB Pharmaceuticals Limited
-
Publication number: 20150246005Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: ApplicationFiled: May 18, 2015Publication date: September 3, 2015Applicant: RB PHARMACEUTICALS LIMITEDInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Patent number: 8975270Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: March 15, 2013Date of Patent: March 10, 2015Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8921387Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 6, 2011Date of Patent: December 30, 2014Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8912211Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.Type: GrantFiled: February 15, 2008Date of Patent: December 16, 2014Assignee: RB Pharmaceuticals LimitedInventors: Christopher Bourne Chapleo, Neil Hyde
-
Patent number: 8697718Abstract: A water- and oxygen-occlusive pack is described. The pack encloses an inert atmosphere containing medicinal tablets, wherein the tablets contain buprenorphine or a salt or ester thereof.Type: GrantFiled: May 14, 2008Date of Patent: April 15, 2014Assignee: RB Pharmaceuticals LimitedInventors: Graham Cairns, John Alfred Davis, Neil Hyde
-
Publication number: 20140005218Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: ApplicationFiled: August 12, 2013Publication date: January 2, 2014Applicant: RB Pharmaceuticals LimitedInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford A. Bogue, Pradeep Sanghvi, Madhusudan Hariharan
-
Publication number: 20130210853Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: June 6, 2011Publication date: August 15, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20130202658Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 6, 2011Publication date: August 8, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Mingxing Zhou
-
Publication number: 20130203796Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventor: RB Pharmaceuticals Limited
-
Patent number: 8497280Abstract: An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to or reaching the plasma of a patient is in the range 22.6:1 to 40:1. The analgesic action of the buprenorphine is potentiated by the low dose of nalmefene. Also provided are a method of treatment of pain and the use of nalmefene and buprenorphine for the manufacture of a medicament.Type: GrantFiled: February 15, 2008Date of Patent: July 30, 2013Assignee: RB Pharmaceuticals LimitedInventors: Christopher Bourne Chapleo, Neil Hyde
-
Patent number: 8475832Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.Type: GrantFiled: August 7, 2009Date of Patent: July 2, 2013Assignee: RB Pharmaceuticals LimitedInventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, B. Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan